Welcome to the e-CCO Library Archive!

search
                             
search by: 
Filter:
P507

Long term outcome of children born to IBD mothers: preliminary result from a multicenter retrospective study in the Netherlands

Authors:

S. Kanis*1, A. De Lima1, Z. Zelinkova1, G. Dijkstra2, R. West3, R. Ouwendijk4, N. De Boer5, M. Pierik6, A. Van der Meulen- De Jong7, L. Oostenbrug8, M. Romberg- Camps9, A. Bodelier10, B. Oldenburg11, F. Hoentjen12, R. Beukers13, J. Jansen14, C. Van der Woude1

1Erasmus Medical Center, Gastroenterology and Hepatology, Rotterdam, Netherlands, 2UMC Groningen, Gastroenterology and Hepatology, Groningen, Netherlands, 3Sint Franciscus Gasthuis, Gastroenterology and Hepatology, Rotterdam, Netherlands, 4Ikazia Hospital, Gastroenterology and Hepatology, Rotterdam, Netherlands, 5VU University Medical Centre, Gastroenterology and Hepatology, Amsterdam, Netherlands, 6Maastricht University Medical Center+, Internal Medicine - Division Gastroenterology-Hepatology, Maastricht, Netherlands, 7LUMC Leiden, Gastroenterology and Hepatology, Leiden, Netherlands, 8Atrium Medical Center, Internal Medicine and Gastroenterology, Heerlen, Netherlands, 9ORBIS Medical Centre, Gastroenterology and Hepatology, Sittard, Netherlands, 10Amphia Hospital, Gastroenterology and Hepatology, Breda, Netherlands, 11UMC Utrecht, Gastroenterology and Hepatology, Utrecht, Netherlands, 12Radboud UMC, Gastroenterology & Hepatology, Nijmegen, Netherlands, 13Albert Schweitzer Hospital, Gastroenterology and Hepatology, Rotterdam, Netherlands, 14Onze Lieve Vrouwe Gasthuis, Gastroenterology and Hepatology, Amsterdam, Netherlands

P508.

Drug survival and reasons for discontinuation of anti-TNF therapy in inflammatory bowel disease (IBD) in clinical practice

Authors:

J.P. Gisbert1, M. Arredondo2, M. Chaparro1, I. Cañamares2, E. Daudén3, G. Fernández-Jiménez4, V. Meca5, A. Morell2, L. Carmona6, J.M. Alvaro-Gracia7, 1Hospital Universitario de La Princesa, IP and CIBERehd, Gastroenterology Unit, Madrid, Spain, 2Hospital Universitario de La Princesa and IP, Farmacy Unit, Madrid, Spain, 3Hospital Universitario de La Princesa and IP, Dermatology Unit, Madrid, Spain, 4Hospital Universitario de La Princesa and IP, Documentation Service, Madrid, Spain, 5Hospital Universitario de La Princesa and IP, Neurology Unit, Madrid, Spain, 6Institute for Musculoskeletal Health, Madrid, Spain, 7Hospital Universitario de La Princesa and IP, Biological Therapies Unit, Madrid, Spain

P508. Evaluation of the diagnostic performance of two commercially available tests for infliximab trough levels (IFX-TL) and antibodies to infliximab (ATI) titration in inflammatory bowel disease (IBD)
Authors:

M. Daperno1, F. Frigerio1, C. Guiotto2, L. Germano2, E. Ercole1, S. Aricò1, M. Fracchia1, C. Rigazio1, A. Lavagna1, R. Pellerito3, M. Migliardi2, R. Rocca1, 1AO Ordine Mauriziano, Gastroenterology Unit, Torino, Italy, 2AO Ordine Mauriziano, Laboratory Unit, Torino, Italy, 3AO Ordine Mauriziano, Rheumatology Unit, Torino, Italy

P508

Vedolizumab for the Treatment of Fistulising Crohn's Disease: An Exploratory Analysis of Data From GEMINI 2

Authors:

B. Feagan*1, D. Schwartz2, S. Danese3, D.T. Rubin4, B. Abhyankar5, M. Smyth6, J. Xu7, K. Lasch8

1Robarts Research Institute, University of Western Ontario, Clinical Trials, London, ON, Canada, 2Inflammatory Bowel Disease Center, Vanderbilt University Medical Center, Medicine, Nashville, TN, United States, 3Istituto Clinico Humanitas, Gastroenterology, Milan, Italy, 4University of Chicago Inflammatory Bowel Disease Center, Gastroenterology, Chicago, IL, United States, 5Takeda Global Research and Development Centre (Europe) Ltd., Clinical Science, London, United Kingdom, 6Takeda Global Research and Development Centre (Europe) Ltd., Medical, London, United Kingdom, 7Takeda Pharmaceuticals International Co., Biostatistics, Cambridge, Massachusetts, United States, 8Takeda Pharmaceuticals International Inc., Medical Affairs, Deerfield, IL, United States

P509.

Do you overlook the Clostridium difficile infection after TB medication?

Authors:

K.C. Huh1, Y.m. Lee1, H.S. Koo1, S.M. Yoon2, Y. Jung3, J.E. Shin4, B.I. Jang5, S.H. Kim6, H.S. Moon7, S.W. Lee8, 1Konyang University College of Medicine, Department of Internal Medicine, Daejeon, Korea, Department of Internal Medicine, Daejeon, Korea, Republic of, 2Chungbuk National University College of Medicine, Department of Internal Medicine, cheongju, Korea, Department of Internal Medicine, Cheongju, Korea, Republic of, 3Soonchunhyang University College of Medicine, Department of Internal Medicine, Cheonan, Korea, Department of Internal Medicine, Cheonan, Korea, Republic of, 4Dankook University College of Medicine, Department of Internal Medicine, Cheonan, Korea, Department of Internal Medicine, Cheonan, Korea, Republic of, 5Yeungnam University College of Medicine, Department of Internal Medicine, Daegu, Korea, Department of Internal Medicine, Daegu, Korea, Republic of, 6Eulji University hospital, Department of Internal Medicine, Daejeon, Korea, Department of Internal Medicine, Daejeon, Korea, Republic of, 7Chungnam National University Hospital, Department of Internal Medicine, Daejeon, Korea, Department of Internal Medicine, Daejeon, Korea, Republic of, 8Catholic University of Korea, Daejeon St. Mary's Hospital, Korea, Department of Internal Medicine, Daejeon, Korea, Republic of

P509. Evaluating clinical practice patterns with inflammatory bowel disease health care assessment questionnaires (POLARIS): a patient- and a physician-reported survey
Authors:

S. Ghosh1, S. Schreiber2, J. Petkau1, B. Bressler3, R.B. Thakkar4, M. Yang4, M. Skup4, J. Chao4, P.M. Mulani4, R. Panaccione1, 1University of Calgary, Calgary, Alberta, Canada, 2Christian-Albrechts University, Kiel, Germany, 3University of British Columbia, Vancouver, Canada, 4Abbott Laboratories, Abbott Park, IL, United States

P509

Risk score for Crohn's Disease activity using red cell distribution width, platelet count, erythrocyte sedimentation rate and C-reactive protein

Authors:

S. Galea*, G. Balzan, P. Ellul, N. Azzopardi

Mater dei Hospital, Gastroenterology, Tal Qroqq, Malta

P510.

Do patients enrolled in pivotal trials represent all inflammatory bowel disease population? EFIFECT study

Authors:

D. Ginard1, S. Khorrami1, L. Pérez-Carazo1, E. Tavío2, A. López-Sanromán2, M. García-Alvaredo3, F. Muñoz3, L. Ibañez4, I. Marín-Jiménez4, J. Guevara5, F. Casellas5, 1Hospital Universitario Son Espases, Gastroenterology, Palma de Mallorca, Spain, 2Hospital Universitario Ramón y Cajal, Gastroenterology, Madrid, Spain, 3Complejo Hospitalario de León, Gastroenterology Unit, León, Spain, 4Hospital Universitario Gregorio Marañón, Gastroenterology, Madrid, Spain, 5Hospital Universitari Vall d'Hebron, Unitat Atenció Crohn-Colitis, Barcelona, Spain

P510. European multicenter trial of budesonide and mesalazine for short-term treatment of active collagenous colitis (BUC60/COC)
Authors:

S. Miehlke1, A. Madisch2, L. Kupcinskas3, D. Petrauskas3, G. Heptner4, G. Böhm5, H.-J. Marks6, M. Neumeyer7, T. Nathan8, F. Fernández-Bañares9, R. Greinwald10, R. Mohrbacher10, M. Vieth11, O. Bonderup12, 1Magen-Darm-Zentrum Eppendorf, Hamburg, Germany, 2Med. Dept. I, Siloah Hospital, Hannover, Germany, 3Lithuanian University of Helath Sciences, Kaunas, Lithuania, 4Private practice, Dresden, Germany, 5Private Practice, Ludwigshafen, Germany, 6Private Practice, Siegen, Germany, 7Private Practice, Oldenburg, Germany, 8Vejle Sygehus, Denmark, 9Hospital Universitario Mutua Terrassa, Spain, 10Dr. Falk Pharma GmbH, Freiburg, Germany, 11Institute for Pathology, Klinkum Bayreuth, Germany, 12Diagnostic Center, Silkeborg Hospital, Denmark

P510

Efficacy and safety of certolizumab pegol in an unselected Crohn's disease population: long-term data of the FACTS III survey

Authors:

S.R. Vavricka1, G. Rogler2, A. Schoepfer3, F. Seibold4, J. Borovicka5, P. Frei6, C.N. Manser2, M. Scharl2, B. Misselwitz2, A. Straumann7, P. Michetti8, L. Biedermann on behalf of Swiss IBDnet *2

1Hospital Triemli, Gastroenterology & Hepatology, Zurich, Switzerland, 2University Hospital Zurich, Division of Gastroenterology & Hepatology, Zurich, Switzerland, 3University Hospital Lausanne, Division of Gastroenterology & Hepatology,, Lausanne, Switzerland, 4Spital Tiefenau, University Hospital Bern, Division of Gastroenterology & Hepatology, Bern, Switzerland, 5Canton Hospital St Gallen, Division of Gastroenterology & Hepatology, St. Gallen, Switzerland, 6Seespital Horgen, Gastroenterology & Hepatology, Horgen, Switzerland, 7Swiss Eosinophilic Esophagitis Research Network, Praxis Römerhof, Olten, Switzerland, 8Clinique La Source-Beaulieu, Crohn and Colitis Center, Lausanne, Switzerland

P511.

Does the location of an IBD centre impact the rates of early postoperative endoscopic recurrence after ileocecal resection in Crohn's disease? Results from the MULTIPER database

Authors:

P.G. Kotze1, T. Yamamoto2, S. Danese3, Y. Suzuki4, I. Albuquerque5, I. Barcelos1, L. Kotze6, M. Olandoski7, F. Teixeira8, R. Silva1, M. Sacchi9, A. Yamada4, R. Saad-Hossne10, A. Spinelli9,11, 1Cajuru University Hospital – Catholic University of Parana, Colorectal Surgery Unit, Curitiba, Brazil, 2Yokkaichi Social Insurance Hospital, IBD Unit, Yokkaichi, Japan, 3Humanitas Research Hospital, IBD Unit – Gastroenterology, Milano, Italy, 4Toho University – Sakura Medical Center, Internal Medicine, Chiba, Japan, 5Heliopolis Hospital, IBD unit, São Paulo, Brazil, 6Cajuru University Hospital – Catholic University of Parana, Gastroenterology, Curitiba, Brazil, 7Catholic University of Paraná, Statistics, Curitiba, Brazil, 8Gastrosaude, Colorectal Surgery, Marilia, Brazil, 9Humanitas Research Hospital, Medical Biotechnologies and Translational Medicine, Milano, Italy, 10São Paulo State University, Digestive Surgery Department, Botucatu, Brazil, 11Humanitas Research Hospital, IBD Surgery Unit, Milano, Italy

P511. Epstein-Barr Virus in inflammatory bowel disease – correlation with different therapeutic regimens
Authors:

F. Magro1, J. Santos-Antunes1, A. Albuquerque1, F. Vilas-Boas1, G.N. Macedo2, N. Nazareth2, S. Lopes1, J. Sobrinho-Simões3, S. Teixeira3, C. Camila-Dias4, J. Cabral5, A. Sarmento2, G. Macedo1, 1Centro Hospitalar S. João, Gastroenterology, Porto, Portugal, 2CEBIMED – Biomedicine Research Center, Faculty of Health Sciences, University Fernando Pessoa, Porto, Portugal, 3Centro Hospitalar S. João, Clinical Pathology Department, Porto, Portugal, 4Faculty of Medicine, University of Porto, CIDES – Department of Health Information and Decision Sciences, Porto, Portugal, 5Faculty of Medicine, University of Porto, Institute of Pharmacology and Therapeutics, Porto, Portugal

P511

Efficacy and safety of granulocyte/monocyte adsorptive apheresis in steroid-dependent Active Ulcerative Colitis with insufficient response or intolerance to immunosuppressants and/or biological therapies (the ART trial): Results at 24 and 48 weeks

Authors:

A. Dignass*1, A. Akbar2, B. Bonaz3

1Agaplesion Markus Hospital, Department of Medicine I, Frankfurt, Germany, 2St Mark's Hospital, Gastroenterology, London, United Kingdom, 3CHU de Grenoble, Clinique Universitaire d'Hépato-Gastroentérologie, Grenoble, France

P512.

Disseminated granuloma annulare associated with Crohn's disease: a rare extraintestinal manifestation

Authors:

M.J. Carrillo1, B. Maldonado1, R. Beltrán1, C. Duarte1, L. Castro1, M. Silla2, Á. Caunedo1, J.M. Herrerías1, 1Hospital Universitario Virgen Macarena, Aparato Digestivo, Sevilla, Spain, 2Hospital Virgen Macarena, Dermatologia, Sevilla, Spain

P512. Elimination of detectable anti-infliximab antibodies and reversal of loss of response by the addition of an immuno-modulator
Authors:

S. Ben-Horin1, M. Waterman2, U. Kopylov1, M. Yavzori1, O. Picard1, E. Fudim1, H. Awadie2, B. Weiss1, Y. Chowers2, 1Sheba Medical Center, Telhashomer, Israel, 2Rambam Health Care Campus & Bruce Rappaport School of Medicine, Technion Israel Institute of Technology, Haifa, Israel

P512

Bowel ultrasound is useful in Crohn's disease monitoring: Analysis from the TRUST study in Germany

Authors:

T. Kucharzik*1, B.M. Wittig2, U. Helwig3, A. Roessler2, S. Rath2, C. Maaser1

1City Hospital Lueneburg, Clinic of Internal Medicine and Gastroenterology, Lueneburg, Germany, 2AbbVie Deutschland GmbH & Co. KG, Medical Department, Wiesbaden, Germany, 3Gastroenterology Practice, IPO, Oldenburg, Germany

P513.

Disparity between infliximab trough level and infliximab associated adverse events

Authors:

V.W. Huang, N. Dhami, D.K. Fedorak, C. Prosser, C. Shalapay, K.I. Kroeker, R.N. Fedorak, University of Alberta, Medicine, Edmonton, Canada

P513. Efficacy of vedolizumab in ulcerative colitis by prior treatment failure in GEMINI I, a randomised, placebo-controlled, double-blind, multi-centre trial
Authors:

B. Feagan1, B. Sands2, S. Sankoh3, C. Milch3, I. Fox3, 1Robarts Research Institute, University of Western Ontario, London, Canada, 2Mount Sinai School of Medicine, Division of Gastroenterology, New York, United States, 3Millennium Pharmaceuticals, Inc., Cambridge, United States

P513

The effect of intravenous iron treament on quality of life in Inflammatory Bowel Disease patients with non-anemic iron deficiency

Authors:

C. Çekiç*, F. Aslan, M. Arabul, S. Ipek, E.S. Yüksel, E. Alper, Z. Akpinar, B. Unsal

Katip Çelebi University, Atatürk Training and Research Hospital, Gastroenterology, Izmir, Turkey

P514.

Disease-specific health-related quality of life in adult patients with mild to moderate ulcerative colitis receiving short-term and long-term daily treatment with MMX mesalazine

Authors:

A.V. Joshi1, A. Yarlas2, M.K. Willian1, 1Shire, Health Economics and Outcomes Research, Wayne, PA, United States, 2Optum, Life Sciences, Lincoln, RI, United States